Craig Hallum started coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC - Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $8.00 price target on the stock.
Separately, Oppenheimer reiterated an outperform rating and set a $6.00 price target (down previously from $7.00) on shares of DiaMedica Therapeutics in a research note on Thursday, March 21st.
View Our Latest Report on DMAC
DiaMedica Therapeutics Stock Up 1.2 %
Shares of NASDAQ:DMAC traded up $0.03 during trading on Wednesday, reaching $2.45. The stock had a trading volume of 7,871 shares, compared to its average volume of 41,350. DiaMedica Therapeutics has a 52 week low of $1.50 and a 52 week high of $4.75. The firm has a market capitalization of $93.00 million, a price-to-earnings ratio of -3.95 and a beta of 1.69. The stock has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $2.70.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). On average, analysts forecast that DiaMedica Therapeutics will post -0.69 EPS for the current year.
Institutional Investors Weigh In On DiaMedica Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the company. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in shares of DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company's stock valued at $1,420,000 after purchasing an additional 30,000 shares in the last quarter. Stonebridge Capital Advisors LLC acquired a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at $52,000. Finally, Avantax Advisory Services Inc. acquired a new stake in shares of DiaMedica Therapeutics in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 10.12% of the company's stock.
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Further Reading
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
